Studies have shown that by using a tri‐specific molecule targeting CLEC12A on AML cells and activating NK cells with a humanized anti‐CD16 single‐domain antibody and IL‐15, the NK cell‐mediated response has a strong effect on primary patient‐derived AML blasts. The gene discussed is IL15; the disease is acute myeloid leukemia.